Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIRB 796 BS in Healthy Subjects
NCT02211144Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2002
- Primary completion
- Nov 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of doramapimod in Crohn's disease, rheumatoid arthritis (RA) and psoriasis (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with clinically significant changes in vital signs, Number of patients with clinically relevant changes in laboratory parameters and 3 more. Started Mar 2002; status: completed.
02
Drugs
doramapimod
03
Conditions
Crohn's diseaserheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NCT02211144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211144.